Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Caribou Biosciences Inc (CRBU)

Caribou Biosciences Inc (CRBU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 148,808
  • Shares Outstanding, K 93,005
  • Annual Sales, $ 9,990 K
  • Annual Income, $ -149,110 K
  • EBIT $ -164 M
  • EBITDA $ -164 M
  • 60-Month Beta 2.48
  • Price/Sales 12.94
  • Price/Cash Flow N/A
  • Price/Book 0.60

Options Overview Details

View History
  • Implied Volatility 124.27% ( -45.80%)
  • Historical Volatility 96.51%
  • IV Percentile 41%
  • IV Rank 24.95%
  • IV High 471.92% on 05/21/25
  • IV Low 8.71% on 10/14/24
  • Put/Call Vol Ratio 0.42
  • Today's Volume 416
  • Volume Avg (30-Day) 198
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 6,671
  • Open Int (30-Day) 5,723

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.40
  • Number of Estimates 4
  • High Estimate -0.35
  • Low Estimate -0.42
  • Prior Year -0.42
  • Growth Rate Est. (year over year) +4.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0400 +68.27%
on 06/16/25
1.7800 -1.69%
on 07/09/25
+0.4800 (+37.80%)
since 06/09/25
3-Month
0.7100 +146.48%
on 04/16/25
1.7800 -1.69%
on 07/09/25
+0.8545 (+95.42%)
since 04/09/25
52-Week
0.6600 +165.15%
on 04/07/25
2.9995 -41.66%
on 11/07/24
+0.1300 (+8.02%)
since 07/09/24

Most Recent Stories

More News
Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference

CRBU : 1.7500 (+9.37%)
Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update

CRBU : 1.7500 (+9.37%)
Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

CRBU : 1.7500 (+9.37%)
Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

CRBU : 1.7500 (+9.37%)
Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

CRBU : 1.7500 (+9.37%)
Caribou Biosciences to Participate in Upcoming Investor Conferences

CRBU : 1.7500 (+9.37%)
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025

CRBU : 1.7500 (+9.37%)
Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

CRBU : 1.7500 (+9.37%)
Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer

CRBU : 1.7500 (+9.37%)
Caribou Biosciences to Participate in Upcoming Investor Conferences

CRBU : 1.7500 (+9.37%)

Business Summary

Caribou Biosciences Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company. It involved in developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors. Caribou Biosciences Inc. is based in...

See More

Key Turning Points

3rd Resistance Point 2.0000
2nd Resistance Point 1.8900
1st Resistance Point 1.8200
Last Price 1.7500
1st Support Level 1.6400
2nd Support Level 1.5300
3rd Support Level 1.4600

See More

52-Week High 2.9995
Fibonacci 61.8% 2.1058
Fibonacci 50% 1.8298
Last Price 1.7500
Fibonacci 38.2% 1.5537
52-Week Low 0.6600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar